-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 9, 2021, the State Food and Drug Administration passed the priority review and approval procedure to approve Zejing Pharmaceutical (688266)'s self-developed category 1 innovative drug Donafenib tosylate (trade name: Zeprosyn) to be marketed.
In patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past
.
In addition, as Donafenib submitted a New Drug Marketing Application (NDA) for locally advanced/metastatic thyroid cancer indications in October, it is expected to have multiple clinical applications in the future
On June 12, the first drug was dispatched smoothly from Zejing Pharmaceutical, and went directly to various commercial channels on the same day, and prescriptions were issued by many hospitals
.
According to the third quarterly report of Zejing Pharmaceuticals, from the first single launch on June 12 to the end of September, a total of 111 days, Zejing Pharmaceuticals achieved operating income of approximately 98.
Public information shows that since its listing, Donafinil has quickly covered 31 provinces (autonomous regions and municipalities), 68 core cities, 127 joint venture cities, 450+ DTP terminal pharmacies, and multiple online and offline platform companies.
Established an experienced marketing team, the core members have more than 10 years of pharmaceutical marketing and management experience, especially in the field of oncology treatment marketing blockbuster products professional promotion experience
.
According to Zejing Pharmaceuticals, Donafenib is the first single-drug head-to-head comparison of large-scale phase I registered clinical trials in the world, and its survival benefit and safety are significantly better than the imported drug Sorafenib.
New anti-tumor drugs
.
Hepatocellular carcinoma (HCC) is the most common tissue type of liver cancer, accounting for 75%-85% of liver cancer
According to public information, Donafenib has been included in the "CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer 2020", "Chinese Expert Consensus on Perioperative Management of Liver Cancer and Liver Resection (2021 Edition)" and "Expert Consensus on Targeted Therapy of Liver Cancer (Draft)-2020" "Expert Consensus on Multidisciplinary Comprehensive Treatment of Liver Cancer in China", "Guidelines for Radiotherapy of Primary Hepatocellular Carcinoma in China (2020 Edition)" and "Guidelines for Clinical Practice of Transarterial Chemoembolization (TACE) Therapy of Liver Cancer in China (2021 Edition)"
.
Zejing Pharmaceuticals said that the company is vigorously promoting Donafinil to enter various guides and insurance catalogs, which is expected to benefit more liver cancer patients
Ten industry insiders pointed out that according to the current medical insurance policy and public information, Donafinil has been listed in the 2021 National Medical Insurance Negotiation Catalogue, and is expected to formally enter the medical insurance catalogue after negotiations.
